Photodynamic therapy: Superficial and interstitial illumination

Journal of Biomedical Optics

Volumn 15, Issue 4, 2010, Pages

  Svanberg, Katarina ^a   Bendsoe, Niels ^a   Axelsson, Johan ^a   Andersson Engels, Stefan ^a   Svanberg, Sune ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Biomedical optics; Lasers in medicine; Photodynamic therapy

Indexed keywords

BIOMEDICAL OPTICS; LASERS IN MEDICINE; LIGHT FLUENCE RATE; LUND UNIVERSITY; OPTICAL DIAGNOSTICS; OXYGEN LEVELS; PROSTATE CANCERS; SKIN TUMOR; THERAPEUTIC DOSE;

DISEASES; LIGHT; PLASMONS; TUMORS; USER INTERFACES;

PHOTODYNAMIC THERAPY;

ARTICLE; EQUIPMENT DESIGN; HUMAN; ILLUMINATION; INSTRUMENTATION; MALE; PHOTOCHEMOTHERAPY; PROSTATE TUMOR; SKIN TUMOR;

EQUIPMENT DESIGN; HUMANS; LIGHTING; MALE; PHOTOCHEMOTHERAPY; PROSTATIC NEOPLASMS; SKIN NEOPLASMS;

EID: 79952199883     PISSN: 10833668     EISSN: 15602281     Source Type: Journal    
DOI: 10.1117/1.3466579     Document Type: Review

References (71)

1. W. Röntgen, "Ûber eine neue Art von Strahlen (Vorläufige Mitteilung )," in Aus den Sitzungsberichten der Würzburger Physik.-Mediz. Gesellschaft 1895, Verlag der Königlicher Hof-u. Universitäts-Buchu. Kunsthandlung, Würzburg (1895).
2. N. R. Finsen, Phototherapy, Edward Arnold, London (1901).
3. F. Urbach, P. D. Forbes, R. E. Davies, and D. Berger, "Cutaneous photobiology: past, present and future," J. Invest. Dermatol. 67, 209-224 (1976).
4. O. Lingjærde, T. Reichborn-Kjennerud, A. Haggag, I. Gärtner, E. M. Berg, and K. Narud, "Treatment of winter depression in Norway. I. Short- and long-term effects of 1500-lux white light for 6 days," Acta Psychiatr. Scand. 88, 292-299 (1993). (Pubitemid 23305189)
5. T. Deguchi, "Circadian rhythm of serotonin N-acetyltransferase activity in organ culture of chicken pineal gland," Science 203, 1245-1247 (1979). (Pubitemid 9149469)
6. O. Raab, "Untersuchungen über die Wirkung fluorescierender Stoffe," Z. Biol. 39, 16 (1899).
7. H. von Tappeiner and A. Jodlbauer, "Über Wirkung der photodynamischen (fluorieszierenden) Stoffe auf Protozoan und Enzyme," Dtsch. Arch. Klin. Med. 80, 427-487 (1904).
8. F. Meyer-Betz, "Untersuchungen über die biologische (photodynamische ) Wirkung des Hämatoporphyrins und andere Derivate des Blut- und Gallenfarbstoffs," Dtsch. Arch. Klin. Med. 112, 476-450 (1913).
9. A. Policard, "Etudes sur les aspects offerts par des tumeur experimentales examinée à la lumière de Woods," C. R. Soc. Biol. 91, 1423 (1924).
10. F. H. J. Figge and G. S. Weiland, "The affinity of neoplastic, embryonic, and traumatized tissue for porphyrins and metalloporphyrins," Anat. Rec. 100, 659 (1948).
11. R. L. Lipson and E. J. Baldes, "The photodynamic properties of a particular haematoporphyrin derivative," Arch. Dermatol. 82, 508-516 (1960).
12. R. Bonnett, M. C. Berenbaum, and H. Kaur, "Chemical and biological studies on haematoporphyrin derivative: an unexpected photosensitisation in brain," in Porphyrins in Tumor Phototherapy, A. Andreoni and R. Cubeddu, Eds., pp. 67-80, Plenum Press, New York (1984).
13. T. J. Dougherty, "Photoradiation in the treatment of recurrent breast carcinoma," J. Natl. Cancer Inst. 62, 231-237 (1979). (Pubitemid 9094709)
14. Z. Huang, "A review of progress in clinical photodynamic therapy," Technol. Cancer Res. Treat. 4, 283-293 (2005). (Pubitemid 40807688)
15. S. S. Stylli and A. H. Kaye, "Photodynamic therapy of cerebral glioma-a review. Part II-clinical studies," J. Clin. Neurosci. 13, 709-717 (2006). (Pubitemid 44354170)
16. N. C. Zeitouni, A. R. Oseroff, and S. Shieh, "Photodynamic therapy for nonmelanoma skin cancers: Current review and update," Mol. Immunol. 39, 1133-1136 (2003). (Pubitemid 36776569)
17. Z. Malik and H. Lugaci, "Destruction of erythroleukaemic cells by photoinactivation of endogenous porphyrins," Br. J. Cancer 56, 589-595 (1987). (Pubitemid 17165652)
18. J. C. Kennedy, R. H. Pottier, and D. C. Pross, "Photodynamic therapy with endogenous protoporphyrin IX: Basic principles and present clinical experience," J. Photochem. Photobiol., B 6, 143-148 (1990).
19. G. Tinghög, P. Carlsson, I. Synnerstad, and I. Rosdahl, "Samhällskostnader för hudcancer samt en jämförelse med kostnaderna för vägtrafikolyckor," Linköping University Electronic Press (2007); http://www.ep.liu.se/ea/cmt/2007/005/.
20. T. J. Dougherty, J. E. Kaufman, A. Goldfarb, K. R. Weishaupt, D. Boyle, and A. Mittleman, "Photoradiation therapy for the treatment of malignant tumors," Cancer Res. 38, 2628-2635 (1978). (Pubitemid 8390848)
21. G. Bandieramonte, R. Marchesini, E. Melloni, C. Andreoli, S. di Pietro, P. Spinelli, G. Fava, F. Zunino, and H. Emanuelli, "Laser phototherapy following HpD administration in superficial neoplastic lesions," Tumori 70, 327-334 (1984). (Pubitemid 14039243)
22. B. D. Wilson, T. S. Mang, M. Cooper, and H. Stoll, "Use of photodynamic therapy for the treatment of extensive basal cell carcinomas," Facial Plast. Surg. 6, 185-189 (1989). (Pubitemid 20250508)
23. D. T. Tse, R. C. Kersten, and R. L. Anderson, "Hematoporphyrin derivative photoradiation therapy in managing nevoid basal-cell carcinoma syndrome," Arch. Ophthalmol 102, 990-994 (1984). (Pubitemid 14083476)
24. J. C. Kennedy and R. H. Pottier, "Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy," J. Photochem. Photobiol., B 14, 275-292 (1992).
25. K. Svanberg, T. Andersson, D. Killander, I. Wang, U. Stenram, S. Andersson-Engels, R. Berg, J. Johansson, and S. Svanberg, "Photodynamic therapy of non-melanoma malignant tumors of the skin using topical 5-amino levulinic acid sensitization and laser irradiation," Br. J. Dermatol. 130, 743-751 (1994). (Pubitemid 24218666)
26. I. Wang, N. Bendsoe, C. af Klinteberg, A. M. K. Enejder, S. Andersson-Engels, S. Svanberg, and K. Svanberg, "Photodynamic therapy vs. cryosurgery of basal cell carcinomas; results of a phase III clinical trial," Br. J. Dermatol. 144, 832-840 (2001). (Pubitemid 32374789)
27. L. Cumberland, A. Dana, and N. Liegeois, "Mohs micrographic surgery for the management of nonmelanoma skin cancers," Facial Plas. Surg. Clin. North Am. 17, 325-335 (2009).
28. P. A. Cowled and I. J. Forbes, "Photocytotoxicity in vivo of haematoporphyrin derivative components," Cancer Lett. 28, 111-118 (1985). (Pubitemid 16245411)
29. T. Windahl, S. O. Andersson, and L. Lofgren, "Photodynamic therapy of localised prostatic cancer," Lancet 336, 1139 (1990). (Pubitemid 20368800)
30. D. Zaak, R. Sroka, M. Höppner, W. Khoder, O. Reich, S. Tritschler, R. Muschter, R. Knüchel, and A. Hofstetter, "Photodynamic therapy by means of 5-ALA induced PPIX in human prostate cancer- preliminary results," Med. Laser Appl. 18, 91-95 (2003). (Pubitemid 36505943)
31. T. R. Nathan, D. E. Whitelaw, S. C. Chang, W. R. Lees, P. M. Ripley, H. Payne, L. Jones, M. C. Parkinson, M. Emberton, A. R. Gillams, A. R. Mundy, and S. G. Bown, "Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study," J. Urol. 168, 1427-1432 (2002). (Pubitemid 35034139)
32. C. M. Moore, T. R. Nathan, W. R. Lees, C. A. Mosse, A. Freeman, M. Emberton, and S. G. Bown, "Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer," Lasers Surg. Med. 38, 356-363 (2006).
33. K. L. Du, R. Mick, T. Busch, T. C. Zhu, J. C. Finlay, G. Yu, A. G. Yodh, S. B. Malkowicz, D. Smith, R. Whittington, D. Stripp, and S. M. Hahn, "Preliminary results of interstitial motexafin lutetiummediated PDT for prostate cancer," Lasers Surg. Med. 38, 427-434 (2006).
34. K. Verigos, D. Stripp, R. Mick, T. Zhu, R. Whittington, D. Smith, A. Dimofte, J. Finlay, T. Busch, Z. Tochner, S. Malkowicz, E. Glatstein, and S. Hahn, "Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer," J. Environ. Pathol. Toxicol. Oncol. 25, 373-387 (2006). (Pubitemid 43341252)
35. T. C. Zhu, A. Dimofte, J. C. Finlay, D. Stripp, T. Busch, J. Miles, R. Whittington, S. B. Malkowicz, Z. Tochner, E. Glatstein, and S. M. Hahn, "Optical properties of human prostate at 732 nm measured in vivo during motexafin lutetium-mediated photodynamic therapy," Photochem. Photobiol. 81, 96-105 (2005). (Pubitemid 40327565)
36. J. C. Finlay, T. C. Zhu, A. Dimofte, D. Stripp, S. B. Malkowicz, T. M. Busch, and S. M. Hahn, "Interstitial fluorescence spectroscopy in the human prostate during motexafin lutetium-mediated photodynamic therapy," Photochem. Photobiol. 82, 1270-1278 (2006). (Pubitemid 44702008)
37. G. Q. Yu, T. Durduran, C. Zhou, T. C. Zhu, J. C. Finlay, T. M. Busch, S. B. Malkowicz, S. M. Hahn, and A. G. Yodh, "Real-time in situ monitoring of human prostate photodynamic therapy with diffuse light," Photochem. Photobiol. 82, 1279-1284 (2006). (Pubitemid 44702009)
38. H. Patel, R. Mick, J. Finlay, T. C. Zhu, E. Rickter, K. A. Cengel, S. B. Malkowicz, S. M. Hahn, and T. M. Busch, "Motexafin lutetiumphotodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen," Clin. Cancer Res. 14, 4869-4876 (2008).
39. M. D. Altschuler, T. C. Zhu, J. Li, and S. M. Hahn, "Optimized interstitial PDT prostate treatment planning with the Cimmino feasibility algorithm," Med. Phys. 32, 3524-3536 (2005).
40. J. Trachtenberg, A. Bogaards, R. A. Weersink, M. A. Haider, A. Evans, S. A. McCluskey, A. Scherz, M. R. Gertner, C. Yue, S. Appu, A. Aprikian, J. Savard, B. C. Wilson, and M. Elhilali, "Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response," J. Urol. 178, 1974-1979 (2007). (Pubitemid 47554440)
41. J. Trachtenberg, R. A. Weersink, S. R. H. Davidson, M. A. Haider, A. Bogaards, M. R. Gertner, A. Evans, A. Scherz, J. Savard, J. L. Chin, B. C. Wilson, and M. Elhilali, "Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses," Br. J. Urol. Int. 102, 556-562 (2008).
42. R. A. Weersink, A. Bogaards, M. Gertner, S. R. H. Davidson, K. Zhang, G. Netchev, J. Trachtenberg, and B. C. Wilson, "Techniques for delivery and monitoring of TOOKAD (WST09)-mediated photodynamic therapy of the prostate: clinical experience and practicalities," J. Photochem. Photobiol. B Biol. 79, 211-222 (2005). (Pubitemid 40668440)
43. M. A. Haider, S. R. H. Davidson, A. V. Kale, R. A. Weersink, A. J. Evans, A. Toi, M. R. Gertner, A. Bogaards, B. C. Wilson, J. L. Chin, M. Elhilali, and J. Trachtenberg, "Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide," Radiology 244, 196-204 (2007). (Pubitemid 46981974)
44. S. Davidson, R. A. Weersink, M. A. Haider, M. R. Gertner, A. Bogaards, D. Giewercer, A. Scherz, M. D. Sherar, M. Elhilali, J. L. Chin, J. Trachtenberg, and B. C. Wilson, "Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer," Phys. Med. Biol. 54, 2293-2313 (2009).
45. M. Stenberg, M. Soto Thompson, T. Johansson, S. Palsson, C. af Klinteberg, S. Andersson-Engels, U. Stenram, S. Svanberg, and K. Svanberg, "Interstitial photodynamic therapy-diagnostic measurements and treatment in malignant experimental rat tumors," in Optical Biopsy and Tissue Optics, I. J. Bigio, G. J. Mueller, G. J. Puppels, R. W. Steiner, and K. Svanberg, Eds., Proc. SPIE 4161, 151-157 (2000).
46. T. Johansson, M. Soto Thompson, M. Stenberg, C. af Klinteberg, S. Andersson-Engels, S. Svanberg, and K. Svanberg, "Feasibility study of a novel system for combined light dosimetry and interstitial photodynamic treatment of massive tumors," Appl. Opt. 41, 1462-1468 (2002). (Pubitemid 34636177)
47. M. Soto Thompson, A. Johansson, T. Johansson, S. Andersson- Engels, N. Bendsoe, K. Svanberg, and S. Svanberg, "Clinical system for interstitial photodynamic therapy with combined on-line dosimetry measurements," Appl. Opt. 44, 4023-4031 (2005). (Pubitemid 40971995)
48. A. Johansson, T. Johansson, M. S. Thompson, N. Bendsoe, K. Svanberg, S. Svanberg, and S. Andersson-Engels, "In vivo measurement of parameters of dosimetric importance during interstitial photodynamic therapy of thick skin tumors," J. Biomed. Opt. 11, 34029 (2006).
49. A. Johansson, N. Bendsoe, K. Svanberg, S. Svanberg, and S. Andersson-Engels, "Influence of treatment-induced changes in tissue absorption on treatment volume during interstitial photodynamic therapy," Med. Laser Appl. 21, 261-270 (2006). (Pubitemid 44636437)
50. A. Johansson, M. Soto Thompson, T. Johansson, N. Bendsoe, K. Svanberg, S. Svanberg, and S. Andersson-Engels, "System for integrated interstitial photodynamic therapy and dosimetric monitoring," Proc. SPIE 5689, 130-140 (2005). (Pubitemid 40953757)
51. A. Johansson, J. Hjelm, E. Eriksson, and S. Andersson-Engels, "Pretreatment dosimetry for interstitial photodynamic therapy," OSA, ECBO Munich (2005).
52. A. Johansson, J. Axelsson, S. Andersson-Engels, and J. Swartling, "Realtime light dosimetry software tools for interstitial photodynamic therapy of the human prostate," Med. Phys. 34, 4309-4321 (2007). (Pubitemid 350029653)
53. M. C. Berenbaum, R. Bonnett, and P. A. Scourides, "In vivo biological activity of the components of haematoporphyrin derivative," Br. J. Cancer 45, 571-581 (1982). (Pubitemid 12100558)
54. J. C. van Gemert, M. C. Berenbaum, and G. H. Gijsbers, "Wavelength and light-dose dependence in tumor phototherapy with haematoporphyrin derivative," Br. J. Cancer 52, 43-49 (1985). (Pubitemid 15061098)
55. A. Dimofte, T. C. Zhu, S. M. Hahn, and R. A. Lustig, "In vivo light dosimetry for motexafin lutetium-mediated PDT of breast cancer," Lasers Surg. Med. 31, 305-312 (2002). (Pubitemid 36008431)
56. L. Lilge, N. Pomerleau-Dalcourt, A. Douplik, S. H. Selman, R. W. Keck, M. Szkudlarek, M. Pestka, and J. Jankun, "Transperineal in vivo fluence-rate dosimetry in the canine prostate during SnET2- mediated PDT," Phys. Med. Biol. 49, 3209-3225 (2004). (Pubitemid 39140008)
57. T. C. Zhu, J. C. Finlay, and S. M. Hahn, "Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in vivo in human prostate during motexafin lutetiummediated photodynamic therapy," J. Photochem. Photobiol. B Biol. 79, 231-241 (2005). (Pubitemid 40668442)
58. K. K. H. Wang and T. C. Zhu, "Reconstruction of in vivo optical properties for human prostate using interstitial diffuse optical tomography," Opt. Express 17, 11665-11672 (2009).
59. Z. Jiang, D. Piao, G. Xu, J. W. Ritchey, G. Holyoak, K. E. Bartels, C. F. Bunting, G. Slobodov, and J. S. Krasinski, "Trans-rectal ultrasound-coupled near-infrared optical tomography of the prostate. Part II: experimental demonstration," Opt. Express 16, 17505-17520 (2008).
60. G. Xu, D. Piao, C. Musgrove, C. Bunting, and H. Dehghani, "Transrectal ultrasound-coupled near-infrared optical tomography of the prostate, part I: simulation," Opt. Express 16, 17484 (2008).
61. C. Li, R. Liengsawangwong, H. Choi, and R. Cheung, "Using a priori structural information from magnetic resonance imaging to investigate the feasibility of prostate diffuse optical tomography and spectroscopy: a simulation study," Med. Phys. 34, 266-274 (2007). (Pubitemid 46035248)
62. W. C. Y. Lo, K. Redmond, J. Luu, P. Chow, J. Rose, and L. Lilge, "Hardware acceleration of a Monte Carlo simulation for photodynamic therapy treatment planning," J. Biomed. Opt. 14, 014019 (2009).
63. D. J. Dickey, R. B. Moore, D. C. Rayner, and J. Tulip, "Light dosimetry using the P3 approximation," Phys. Med. Biol. 46, 2359-2370 (2001). (Pubitemid 32895532)
64. D. J. Dickey, K. Partridge, R. B. Moore, and J. Tulip, "Light dosimetry for multiple cylindrical diffusing sources for use in photodynamic therapy," Phys. Med. Biol. 49, 3197-3208 (2004). (Pubitemid 39140007)
65. J. Li, M. D. Altschuler, S. M. Hahn, and T. C. Zhu, "Optimization of light source parameters in the photodynamic therapy of heterogeneous prostate," Phys. Med. Biol. 53, 4107-4121 (2008).
66. A. Rendon, J. C. Beck, and L. Lilge, "Treatment planning using tailored and standard cylindrical light diffusers for photodynamic therapy of the prostate," Phys. Med. Biol. 53, 1131-1149 (2008). (Pubitemid 351238128)
67. A. Johansson, J. Axelsson, J. Swartling, T. Johansson, S. Palsson, J. Stensson, M. Einarsdottir, K. Svanberg, N. Bendsoe, K. M. Kalkner, S. Nilsson, S. Svanberg, and S. Andersson-Engels, "Interstitial photodynamic therapy for primary prostate cancer incorporating realtime treatment dosimetry," in Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy, D. Kessel, Ed., Proc. SPIE 6427, 642700 (2007).
68. J. Swartling, J. Axelsson, S. Svanberg, S. Andersson-Engels, K. Svanberg, G. Ahlgren, K. M. Kälkner, and S. Nilsson, "System for interstitial photodynamic therapy with on-line dosimetry-first clinical experiences of prostate cancer" (unpublished).
69. C. Sheng, P. Jack Hoopes, T. Hasan, and B. W. Pogue, " Photobleaching-based dosimetry predicts deposited dose in ALAPpIX PDT of rodent esophagus," Photochem. Photobiol. 83, 738-748 (2007). (Pubitemid 46854943)
70. X. D. Zhou, B. W. Pogue, B. Chen, E. Demidenko, R. Joshi, J. Hoopes, and T. Hasan, "Pretreatment photosensitizer dosimetry reduces variation in tumor response," Int. J. Radiat. Oncol., Biol., Phys. 64, 1211-1220 (2006).
71. J. Axelsson, J. Swartling, and S. Andersson-Engels, "In vivo photosensitizer tomography inside the human prostate," Opt. Lett. 34, 232-234 (2009).